Nurix Therapeutics (NRIX): Assessing Valuation After a Sharp Multi-Month Share Price Rebound

Simply Wall St.12-16 12:34

Nurix Therapeutics (NRIX) has quietly turned heads with a sharp rebound, with the stock up roughly 49% over the past month and more than doubling in the past 3 months. See our latest analysis for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591198892?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-12-16 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591198892","market":"hk","top_or_hot":-1,"title":"Nurix Therapeutics (NRIX): Assessing Valuation After a Sharp Multi-Month Share Price Rebound","media":"Simply Wall St.","content":"<div>\n<p>Nurix Therapeutics (NRIX) has quietly turned heads with a sharp rebound, with the stock up roughly 49% over the past month and more than doubling in the past 3 months. See our latest analysis for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-assessing-valuation-after-a-sharp-mu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nurix Therapeutics (NRIX): Assessing Valuation After a Sharp Multi-Month Share Price Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNurix Therapeutics (NRIX): Assessing Valuation After a Sharp Multi-Month Share Price Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-16 12:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-assessing-valuation-after-a-sharp-mu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nurix Therapeutics (NRIX) has quietly turned heads with a sharp rebound, with the stock up roughly 49% over the past month and more than doubling in the past 3 months. See our latest analysis for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-assessing-valuation-after-a-sharp-mu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRIX","symbol_name":"Nurix Therapeutics","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-assessing-valuation-after-a-sharp-mu","article_id":"2591198892","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-assessing-valuation-after-a-sharp-mu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591198892","pubTimestamp":1765859641,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Nurix Therapeutics (NRIX) has quietly turned heads with a sharp rebound, with the stock up roughly 49% over the past month and more than doubling in the past 3 months.\nSee our latest analysis for Nurix Therapeutics.\nThat surge has helped claw back some ground after a tougher stretch, with a 30 day share price return of 48.5% and a three year total shareholder return of 70.0% suggesting positive momentum is rebuilding from a still volatile base.\nIf Nurix’s rebound has you rethinking biotech...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRIX":"Nurix Therapeutics","BK4139":"生物科技"},"translate_title":"Nurix Therapeutics(NRIX)：股价数月大幅反弹后评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":1.5},"content_text":"Nurix Therapeutics (NRIX) has quietly turned heads with a sharp rebound, with the stock up roughly 49% over the past month and more than doubling in the past 3 months. See our latest analysis for Nurix Therapeutics. That surge has helped claw back some ground after a tougher stretch, with a 30 day share price return of 48.5% and a three year total shareholder return of 70.0% suggesting positive momentum is rebuilding from a still volatile base. If Nurix’s rebound has you rethinking biotech risk and reward, it might be worth widening the lens and exploring healthcare stocks for more ideas in the space. Yet despite the rally, Nurix still trades at a steep discount to Wall Street targets. That raises a key question: Are investors staring at an overlooked biotech bargain, or is the market already baking in the next leg of growth? Price-to-Sales of 23.1x: Is it justified? On a preferred price to sales yardstick, Nurix’s 19.01 dollar share price bakes in a far richer valuation profile than both peers and fair value estimates. The price to sales ratio compares a company’s market value to its revenue, a common way to value early stage or unprofitable biotechs where earnings are negative. For Nurix, this lens suggests investors are paying a high premium for each dollar of current sales, implying strong confidence in future commercialization and pipeline success despite ongoing losses. Nurix’s price to sales multiple of 23.1 times stands well above the broader US biotechs industry average of 12.1 times and also exceeds the peer group’s 17.9 times benchmark, signaling a markedly richer valuation than comparable names. Even more striking, it trades dramatically higher than the estimated fair price to sales ratio of 0.2 times, a level that highlights how far sentiment and expectations could need to adjust if markets gravitate toward that fair ratio anchor. Explore the SWS fair ratio for Nurix Therapeutics Result: Price-to-Sales of 23.1x (OVERVALUED) However, substantial ongoing losses and clinical or partnership setbacks could quickly deflate sentiment and challenge the lofty valuation despite recent momentum. Find out about the key risks to this Nurix Therapeutics narrative.  Build Your Own Nurix Therapeutics Narrative If you see things differently or want to dig into the numbers yourself, you can build a personalized view in just a few minutes: Do it your way. A great starting point for your Nurix Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision. Looking for your next move? Before you move on, lock in your edge by using the Simply Wall Street Screener to uncover focused stock ideas that many investors are still overlooking.  Target potential bargains trading below their intrinsic worth by scanning these 908 undervalued stocks based on cash flows built on detailed cash flow analysis. Capitalize on the next wave of intelligent automation by zeroing in on these 26 AI penny stocks with compelling growth stories. Strengthen your income strategy by filtering for reliable payers using these 13 dividend stocks with yields > 3% that support yields above 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentValuation is complex, but we're here to simplify it.Discover if Nurix Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591198892","isCrawlerRequest":true}